Corpus overview


MeSH Disease

Human Phenotype

Hypertension (73)

Fever (21)

Cough (19)

Obesity (19)

Dyspnea (13)


    displaying 1 - 10 records in total 73
    records per page

    Patterns of Multimorbidity and Risk of Severe SARS-CoV-2 Infection MESHD: an observational study in the U.K.

    Authors: Yogini V Chudasama; Francesco Zaccardi; Clare L Gillies; Cameron Razieh; Thomas Yates; David E Kloecker; Alex V Rowlands; Melanie J Davies; Nazrul Islam; Samuel Seidu; Nita G Forouhi; Kamlesh Khunti; Deverick J. Anderson; Jimmie Mancell; David Ho; Nathan D. Grubaugh; Yonatan H. Grad; Riina Janno; Irja Lutsar; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20216721 Date: 2020-10-23 Source: medRxiv

    Background Pre-existing comorbidities have been linked to SARS-CoV-2 infection MESHD but evidence is sparse on the importance and pattern of multimorbidity (2 or more conditions) and severity of infection MESHD indicated by hospitalisation or mortality. We aimed to use a multimorbidity index developed specifically for COVID-19 to investigate the association between multimorbidity and risk of severe SARS-CoV-2 infection MESHD. Methods We used data from the UK Biobank linked to laboratory confirmed test results for SARS-CoV-2 infection MESHD and mortality data from Public Health England between March 16 and July 26, 2020. By reviewing the current literature on COVID-19 we derived a multimorbidity index including: 1) angina MESHD; 2) asthma HP; 3) atrial fibrillation HP atrial fibrillation MESHD; 4) cancer MESHD; 5) chronic kidney disease HP kidney disease MESHD; 6) chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD; 7) diabetes mellitus HP diabetes mellitus MESHD; 8) heart failure MESHD; 9) hypertension HP hypertension MESHD; 10) myocardial infarction HP myocardial infarction MESHD; 11) peripheral vascular disease MESHD; 12) stroke HP stroke MESHD. Adjusted logistic regression models were used to assess the association between multimorbidity and risk of severe SARS-CoV-2 infection MESHD (hospitalisation or death MESHD). Potential effect modifiers of the association were assessed: age TRANS, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25-hydroxyvitamin D, cardiorespiratory fitness MESHD, high sensitivity SERO C-reactive protein. Results Among 360,283 participants, the median age TRANS was 68 [range, 48-85] years, most were White (94.5%), and 1,706 had severe SARS-CoV-2 infection MESHD. The prevalence SERO of multimorbidity was more than double in those with severe SARS-CoV-2 infection MESHD (25%) compared to those without (11%), and clusters of several multimorbidities were more common in those with severe SARS-CoV-2 infection MESHD. The most common clusters with severe SARS-CoV-2 infection MESHD were stroke HP stroke MESHD with hypertension HP hypertension MESHD (79% of those with stroke HP stroke MESHD had hypertension HP hypertension MESHD); diabetes MESHD and hypertension HP hypertension MESHD (72%); and chronic kidney disease HP chronic kidney disease MESHD and hypertension HP hypertension MESHD (68%). Multimorbidity was independently associated with a greater risk of severe SARS-CoV-2 infection MESHD (adjusted odds ratio 1.91 [95% confidence interval 1.70, 2.15] compared to no multimorbidity). The risk remained consistent across potential effect modifiers, except for greater risk among men. Conclusion The risk of severe SARS-CoV-2 infection MESHD is higher in individuals with multimorbidity, indicating the need to target research and resources in people with SARS-CoV-2 infection MESHD and multimorbidity.

    Multi-organ impairment in low-risk individuals with long COVID

    Authors: Andrea Dennis; Malgorzata Wamil; Sandeep Kapur; Johann Alberts; Andrew Badley; Gustav Anton Decker; Stacey A Rizza; Rajarshi Banerjee; Amitava Banerjee; Mauro Giudici; Giovanni Naldi; Sabrina Gaito; Silvana Castaldi; Elia Biganzoli; Sachee Agrawal; Chandrakant Pawar; Mala Kaneria; Smita Mahale; Jayanthi Shastri; Vainav Patel; Paul Dark; Alexander Mathioudakis; Kathryn Gray; Graham Lord; Timothy Felton; Chris Brightling; Ling-Pei Ho; - NIHR Respiratory TRC; - CIRCO; Karen Piper Hanley; Angela Simpson; John R Grainger; Tracy Hussell; Elizabeth R Mann

    doi:10.1101/2020.10.14.20212555 Date: 2020-10-16 Source: medRxiv

    Background: Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection MESHD has disproportionately affected older individuals and those with underlying medical conditions. Research has focused on short-term outcomes in hospital, and single organ involvement. Consequently, impact of long COVID (persistent symptoms three months post-infection) across multiple organs in low-risk individuals is yet to be assessed. Methods: An ongoing prospective, longitudinal, two-centre, observational study was performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection MESHD. Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed by standardised questionnaires (EQ-5D-5L, Dyspnoea-12 MESHD), blood SERO investigations and quantitative magnetic resonance imaging, defining single and multi-organ impairment by consensus definitions. Findings: Between April and September 2020, 201 individuals (mean age TRANS 44 (SD 11.0) years, 70% female TRANS, 87% white, 31% healthcare workers) completed assessments following SARS-CoV-2 infection MESHD (median 140, IQR 105-160 days after initial symptoms). The prevalence SERO of pre-existing conditions ( obesity HP obesity MESHD: 20%, hypertension HP hypertension MESHD: 6%; diabetes MESHD: 2%; heart disease MESHD: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19. Fatigue HP (98%), muscle aches MESHD (88%), breathlessness (87%), and headaches HP headaches MESHD (83%) were the most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were common, and 42% of individuals had ten or more symptoms. There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%), liver (10%), pancreas MESHD (17%), and spleen (6%). Single (66%) and multi-organ (25%) impairment was observed, and was significantly associated with risk of prior COVID-19 hospitalisation (p<0.05). Interpretation: In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in one or more organs four months after initial symptoms of SARS-CoV-2 infection MESHD. There are implications not only for burden of long COVID but also public health approaches which have assumed low risk in young people with no comorbidities.

    Incidence and Risk Factors of Illnesses Presumably Caused by A SARS-CoV-2 Infection MESHD in The General Population During The Lockdown Period: A Multi-Cohort Study.

    Authors: Fabrice Carrat; Mathilde Touvier; Gianluca Severi; Laurence Meyer; Florence Jusot; Nathanael Lapidus; Delphine Rahib; Nathalie Lydié; Marie-Aline Charles; Pierre-Yves Ancel; Alexandra Rouquette; Xavier de Lamballerie; Marie Zins; Nathalie Bajos

    doi:10.21203/ Date: 2020-10-10 Source: ResearchSquare

    Background Our main objectives were to estimate the incidence of illnesses presumably caused by SARS-CoV-2 infection MESHD during the lockdown period and to identify the associated risk factors.Methods Participants from 3 adult TRANS cohorts in the general population in France were invited to participate in a survey on COVID-19. The main outcome was possible COVID-19, defined as a sudden onset of cough HP, fever HP fever MESHD, dyspnea HP dyspnea MESHD, ageusia and/or anosmia HP anosmia MESHD, that lasted more than 3 days and occurred during the 17 days before the survey. We used delayed-entry Cox models to identify associated factors.Results Between April 2, 2020 and May 12, 2020, 279,478 participants were invited, 116,903 validated the questionnaire and 106,848 were included in the analysis. Three thousand thirty-five cases of possible COVID-19 were reported during 62,099 person-months of follow-up. The cumulative incidences of possible COVID-19 were 6.2% (95% Confidence Interval (95%CI): 5.7%; 6.6%) on day 15 and 8.8% (95%CI 8.3%; 9.2%) on day 45 of lockdown. The risk of possible COVID-19 was lower in older age groups TRANS and higher in French regions with a high prevalence SERO of SARS-CoV-2 infection MESHD, in participants living in cities >100,000 inhabitants (vs rural areas), when at least one child TRANS or adolescent was living in the same household, in overweight HP or obese people MESHD, and in people with chronic respiratory diseases MESHD, anxiety HP anxiety MESHD or depression or chronic diseases MESHD other than diabetes MESHD, cancer MESHD, hypertension HP hypertension MESHD or cardiovascular diseases MESHD. Conclusion The incidence of possible COVID-19 in the general population remained high during the first two weeks of lockdown, and decreased significantly thereafter. Modifiable and non-modifiable risk factors were identified.

    A national study of self-reported COVID symptoms during the first viral wave in Canada

    Authors: Xuyang Tang; Hellen Gelband; Teresa Lam; Nico Nagelkerke; Angus Reid; Prabhat Jha; - Action to beat Coronavirus (Ab-C) Study Investigators; Jakob Trimpert; Jens Bukh; Klaus Osterrieder; Judith Gottwein; Peter H Seeberger; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205930 Date: 2020-10-05 Source: medRxiv

    Importance: Accurate understanding of COVID pandemic during the first viral wave in Canada could help prepare for future epidemic waves. Objective: To track the early course of the pandemic by examining self-reported COVID symptoms over time before testing became widely available. Design: Adults TRANS from the nationally representative Angus Reid Forum were randomly invited to complete an online survey in May/June 2020. The study is a part of the Action to Beat Coronavirus antibody testing SERO study. Setting: A 20-item internet survey. Participants: 14,408 adults TRANS age TRANS 18 years of age TRANS. Exposures: The months that respondents and any household members first experienced various respiratory, neurological, sleep, skin or gastric symptoms MESHD. Main Outcomes and Measure: COVID symptom-positive, defined as fever HP fever MESHD (or fever HP fever MESHD with hallucinations HP hallucinations MESHD) plus at least one of difficulty breathing, a dry severe cough HP, loss of smell or COVID toe. Results: In total, 14,408 panel members (48% male TRANS and 52% female TRANS) completed the survey. Despite overrepresentation of higher levels of education, the prevalence SERO of obesity HP obesity MESHD, smoking, diabetes MESHD and hypertension HP hypertension MESHD were similar to national census and health surveys. A total of 811 (5.6%) were COVID symptom-positive; highest rates were at ages TRANS 18-44 years (8.3% among), declining at older ages TRANS. Females TRANS had higher odds of reporting COVID symptoms (OR = 1.32, 95%CI 1.11-1.56) as did visible minorities (OR = 1.74, 1.29-2.35). COVID symptom positivity for respondents and their household members peaked in March (OR = 1.93, 95% CI = 1.59-2.34 compared to earlier months). Conclusions and Relevance: This study enhances our current understanding of the progression of the COVID epidemic in Canada, with few laboratory- confirmed cases TRANS in January and February, peaking in April. The results suggest substantial viral transmission TRANS in March, before widespread testing began, and a gradual decline in cases since May.

    Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study

    Authors: Didier Collard; Nick S. Nurmohamed; Yannick Kaiser; Laurens F. Reeskamp; Tom Dormans; Hazra Moeniralam; Suat Simsek; Renee A. Douma; Annet Eerens; Auke C. Reidinga; Paul W.G. Elbers; Martijn Beudel; Liffert Vogt; Erik S.G. Stroes; Bert-Jan H. van den Born

    doi:10.1101/2020.10.01.20205229 Date: 2020-10-02 Source: medRxiv

    Objectives: Recent reports suggest a high prevalence SERO of hypertension HP hypertension MESHD and diabetes MESHD in COVID-19 patients, but the role of cardiovascular disease MESHD ( CVD MESHD) risk factors in the clinical course of COVID-19 is unknown. We evaluated the time-to-event relationship between hypertension HP hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, and COVID-19 outcomes. Design: We analyzed data from the prospective Dutch COVID-PREDICT cohort, an ongoing prospective study of patients admitted for COVID-19 infection MESHD. Setting: Patients from 8 participating hospitals, including two university hospitals from the COVID-PREDICT cohort were included. Participants: Admitted, adult TRANS patients with a positive COVID-19 polymerase chain reaction (PCR) or high suspicion based on CT-imaging of the thorax. Patients were followed for major outcomes during hospitalization. CVD MESHD risk factors were established via home medication lists and divided in antihypertensives, lipid lowering therapy, and antidiabetics. Primary and secondary outcomes measures: The primary outcome was mortality during the first 21 days following admission, secondary outcomes consisted of ICU-admission and ICU-mortality. Kaplan-Meier and Cox-regression analyses were used to determine the association with CVD MESHD risk factors. Results: We included 1604 patients with a mean age TRANS of 66+-15 of whom 60.5% were men. Antihypertensives, lipid lowering therapy, and antidiabetics were used by 45%, 34.7%, and 22.1% of patients. After adjustment for age TRANS and sex, the presence of [≥]2 risk factors was associated with increased mortality risk (HR 1.52, 95%CI 1.15-2.02), but not with ICU-admission. Moreover, the use of [≥]2 antidiabetics and [≥]2 antihypertensives was associated with mortality independent of age TRANS and sex with HRs of respectively 2.09 (95%CI 1.55-2.80) and 1.46 (95%CI 1.11-1.91). Conclusions: The accumulation of hypertension HP hypertension MESHD, dyslipidemia MESHD and diabetes MESHD leads to a stepwise increased risk for short-term mortality in hospitalized COVID-19 patients independent of age TRANS and sex. Further studies investigating how these risk factors disproportionately affect COVID-19 patients are warranted.

    Clinical Course And Risk Factors For In-hospital Death In Critical COVID-19 In Wuhan, China

    Authors: Fei Li; Yue Cai; Chao Gao; Lei Zhou; Renjuan Chen; Kan Zhang; Weiqin Li; Ruining Zhang; Xijing Zhang; Duolao Wang; Yi Liu; Ling Tao; Jean-Francois Carod; Stephanie Eustache; Celine Tourbillon; Elodie Boizon; Samantha James; Felix Djossou; Henrik Salje; Simon Cauchemez; Dominique Rousset; Ana F. Bernardes; Thyago A. Nunes; Luciana C. Ribeiro; Marcus V. Agrela; Maria Luiza Moretti; Lucas I. Buscaratti; Fernanda Crunfli; Raissa . G Ludwig; Jaqueline A. Gerhardt; Renata Seste-Costa; Julia Forato; Mariene . R Amorin; Daniel A. T. Texeira; Pierina L. Parise; Matheus C. Martini; Karina Bispo-dos-Santos; Camila L. Simeoni; Fabiana Granja; Virginia C. Silvestrini; Eduardo B. de Oliveira; Vitor M. Faca; Murilo Carvalho; Bianca G. Castelucci; Alexandre B. Pereira; Lais D. Coimbra; Patricia B. Rodrigues; Arilson Bernardo S. P. Gomes; Fabricio B. Pereira; Leonilda M. B. Santos; Andrei C. Sposito; Robson F. Carvalho; Andre S. Vieira; Marco A. R. Vinolo; Andre Damasio; Licio A. Velloso; Helder I. Nakaya; Henrique Marques-Souza; Rafael E. Marques; Daniel Martins-de-Souza; Munir S. Skaf; Jose Luiz Proenca-Modena; Pedro M. Moraes-Vieira; Marcelo A. Mori; Alessandro S. Farias

    doi:10.1101/2020.09.26.20189522 Date: 2020-09-28 Source: medRxiv

    BACKGROUND The risk factors for mortality of COVID-19 classified as critical type have not been well described. OBJECTIVES This study aimed to described the clinical outcomes and further explored risk factors of in-hospital death for COVID-19 classified as critical type. METHODS This was a single-center retrospective cohort study. From February 5, 2020 to March 4, 2020, 98 consecutive patients classified as critical COVID-19 were included in Huo Shen Shan Hospital. The final date of follow-up was March 29, 2020. The primary outcome was all-cause mortality during hospitalization. Multivariable Cox regression model was used to explore the risk factors associated with in-hospital death. RESULTS Of the 98 patients, 43 (43.9%) died in hospital, 37(37.8%) discharged, and 18(18.4%) remained in hospital. The mean age TRANS was 68.5 (63, 75) years, and 57 (58.2%) were female TRANS. The most common comorbidity was hypertension HP hypertension MESHD (68.4%), followed by diabetes MESHD (17.3%), angina pectoris HP angina pectoris MESHD (13.3%). Except the sex ( Female TRANS: 68.8% vs 49.1%, P=0.039) and angina pectoris HP angina pectoris MESHD (20.9% vs 7.3%, P = 0.048), there was no difference in other demographics and comorbidities between non-survivor and survivor groups. The proportion of elevated alanine aminotransferase, creatinine, D-dimer and cardiac injury MESHD marker were 59.4%, 35.7%, 87.5% and 42.9%, respectively, and all showed the significant difference between two groups. The acute cardiac injury MESHD injury, acute kidney HP acute kidney injury MESHD ( AKI MESHD), and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) were observed in 42.9%, 27.8% and 26.5% of the patients. Compared with survivor group, non-survivor group had more acute cardiac injury MESHD (79.1% vs 14.5%, P<0.0001), AKI MESHD (50.0% vs 10.9%, P<0.0001), and ARDS MESHD (37.2% vs 18.2%, P=0.034). Multivariable Cox regression showed increasing hazard ratio of in-hospital death associated with acute cardiac injury MESHD (HR, 6.57 [95% CI, 1.89-22.79]) and AKI MESHD (HR, 2.60 [95% CI, 1.15-5.86]). CONCLUSIONS COVID-19 classified as critical type had a high prevalence SERO of acute cardiac and kidney injury MESHD, which were associated with a higher risk of in-hospital mortality.

    Features of patients that died for COVID-19 in a Hospital in the south of Mexico: A observational cohort study

    Authors: Jesus Arturo Ruiz-Quinonez Sr.; Crystell Guzman-Priego Sr.; German Alberto Nolasco-Rosales Sr.; Carlos Alfonso Tovilla-Zarate; Oscar Israel Flores-Barrientos; Victor Narvaez-Osorio; Guadalupe del Carmen Baeza-Flores; Thelma Beatriz Gonzalez-Castro; Carlos Ramon Lopez-Brito; Carlos Alberto Denis-Garcia; Agustin Perez-Garcia; Isela Esther Juarez-Rojop; Zhen Cui; Qing Ye; Geng Chen; Kui-Kui Lu; Yin Chen; Yu-Tao Chen; Hong-Xing Pan; Bao-Li Zhu; Cheng-Feng Qin; Xiangxi Wang; Feng-Cai Zhu

    doi:10.1101/2020.09.21.20199117 Date: 2020-09-23 Source: medRxiv

    Background: Due to the wide spread of SARS-CoV2 around the world, the risk of death MESHD in individuals with metabolic comorbidities has dangerously increased. Mexico has a high number of infected individuals and deaths by COVID-19, as well as an important burden of metabolic diseases MESHD. However, reports about features of Mexican individuals with COVID-19 are scarce. The aim of this study was to evaluate demographic features, clinical characteristics, and the pharmacological treatment of individuals who died by COVID-19 in the south of Mexico. Methods: We performed an observational study including 185 deceased individuals with confirmed diagnosis of COVID-19. Data were retrieved from medical records. Categorical data was expressed as proportions (%) and numerical data were expressed as mean, standard deviation. Comorbidities and overlapping symptoms where plotted as Venn diagrams. Drug clusters were plotted as dendrograms. Results: The mean age TRANS was 59.53 years. There was a male TRANS predominance (60.1%). The mean hospital stay was 4.75 days. The most frequent symptoms were dyspnea HP dyspnea MESHD (88.77%), fever HP fever MESHD (71.42%) and dry cough MESHD cough HP (64.28%). Present comorbidities were diabetes MESHD (60.63%), hypertension HP hypertension MESHD (59.57%) and obesity HP obesity MESHD (43.61%). The main drugs used were azithromycin (60.6%), hydroxychloroquine (53.0%) and oseltamivir (27.3%). Conclusions: Mexican individuals who died of COVID-19 had shorter hospital stays, higher frequency of shortness of breath MESHD, and higher prevalence SERO of diabetes MESHD compared with individuals from other countries. Also, there was a high frequency of off-label use of drugs for their treatment.

    Ruling In and Ruling Out COVID-19: Computing SARS-CoV-2 Infection Risk TRANS Infection Risk TRANS From Symptoms, Imaging and Test Data.

    Authors: Chistopher D'Ambrosia; Henrik Christensen; Eliah Aronoff-Spencer

    doi:10.1101/2020.09.18.20197582 Date: 2020-09-22 Source: medRxiv

    Background: Assigning meaningful probabilities of SARS CoV2 infection risk TRANS infection risk TRANS presents a diagnostic challenge across the continuum of care. Methods: We integrated patient symptom and test data using machine learning and Bayesian inference to quantify individual patient risk of SARS CoV 2 infection MESHD. We trained models with 100,000 simulated patient profiles based on thirteen symptoms, estimated local prevalence SERO, imaging, and molecular diagnostic performance SERO from published reports. We tested these models with consecutive patients who presented with a COVID 19 compatible illness at the University of California San Diego Medical Center over 14 days starting in March 2020. Results: We included 55 consecutive patients with fever HP fever MESHD (78%) or cough HP cough MESHD (77%) presenting for ambulatory (n=11) or hospital care (n=44). 51% (n=28) were female TRANS, 49% were age TRANS <60. Common comorbidities included diabetes MESHD (22%), hypertension HP hypertension MESHD (27%), cancer MESHD (16%) and cardiovascular disease MESHD (13%). 69% of these (n=38) were RT-PCR confirmed positive for SARS CoV2 infection, 11 had repeated negative nucleic acid testing and an alternate diagnosis. Bayesian inference network, distance metric learning, and ensemble models discriminated between patients with SARS CoV2 infection MESHD and alternate diagnoses with sensitivities SERO of 81.6 to 84.2%, specificities of 58.8 to 70.6%, and accuracies of 61.4 to 71.8%. After integrating imaging and laboratory test statistics with the predictions of the Bayesian inference network, changes in diagnostic uncertainty at each step in the simulated clinical evaluation process were highly sensitive to location, symptom, and diagnostic test choices. Conclusions: Decision support models that incorporate symptoms and available test results can help providers diagnose SARS CoV2 infection MESHD in real world settings.

     Seroprevalence of SARS-CoV-2 in an Asymptomatic TRANS US Population 

    Authors: Steven Rigatti, MD; Robert L. Stout, PhD.

    doi:10.21203/ Date: 2020-09-18 Source: ResearchSquare

    Methods: We performed SARS-CoV-2 antibody SERO tests with the Roche e602 SARS CoV-2 Immuno system on 50,257 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting mortality risk. Other variables included height, weight, and blood SERO pressure at the time of the blood SERO draw, a history of smoking and common ch ronic diseases ( MESHD hypertension HP pertension, MESHDhe art disease, MESHDdi abetes, MESHDand ca ncer). MESHDResults: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using US Census state population data to adjust state specific rates of positivity, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SA RS-CoV-2 infections i MESHDn the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020.Conclusions: The estimated number of total SA RS-CoV-2 infections b MESHDased on positive serology is substantially higher than the total number of cases reported to the CDC. There is no apparent increase of risk of infection TRANS risk of infection TRANS fection f MESHDor individuals self-reporting, smoking, di abetes, MESHDhe art disease, MESHD hypertension HP pertension o MESHDr ca ncer. MESHD

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients

    Authors: Samson Barasa; David Tarazona; Faviola Valdivia Guerrero; Nancy Rojas Serrano; Dennis Carhuaricra; Lenin Maturrano Hernandez; Ronnie Gavilan Chavez

    doi:10.1101/2020.09.11.20192963 Date: 2020-09-13 Source: medRxiv

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients Samson Barasa,1 Amy Ballard,1 Josephine Kiage-Mokaya, 1 Michael Friedlander,1 Geraldine Luna,2 1PeaceHealth Sacred Heart 2University of Illinois at Chicago Introduction: Increasing corona virus disease MESHD 2019 (COVID-19) pre-test probability can minimize testing patients who are less likely to have COVID-19 and therefore reducing personal protective equipment and COVID-19 testing kit use. The aim of this study was to identify patients who were likely to test positive for COVID-19 among symptomatic patients suspected of having COVID-19 during hospitalization by comparing COVID-19 positive and negative patients. Method: We conducted a retrospective chart review of patients who were [≥]18 years old and underwent COVID-19 Polymerase chain reaction test because they presented with symptoms thought to be due to COVID-19. A Poisson regression analysis was conducted after clinical presentation, demographic, medical co-morbidities, laboratory and chest image data was retrieved from the medical records. Results: Charts of 277 and 18 COVID-19 negative and positive patients respectively were analyzed. Dyspnea HP Dyspnea MESHD (61%) was the most common symptom among COVID-19 negative patients, while 72% and 61% COVID-19 positive patients had cough HP cough MESHD and fever HP fever MESHD respectively. COVID-19 positive patients were more likely to present initially with cough HP [1.082 (1.022 - 1.145)], fever HP fever MESHD [1.066 (1.014 - 1.121)] and be 50 to 69 years old [1.094 (1.021 - 1.172)]. Dyspnea HP Dyspnea MESHD, weakness MESHD, lymphopenia HP lymphopenia MESHD and bilateral chest image abnormality were not associated with COVID-19 positivity. COVID-19 positive patients were less likely to have non-COVID-19 respiratory viral illness [1.068 (1.019 - 1.119)], human immunodeficiency HP immunodeficiency MESHD virus [0.849 (0.765 - 0.943)] and heart failure MESHD history [0.093 (0.891 - 0.978)]. Other chronic medical problems ( hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD and coronary artery disease MESHD) were not associated with testing positive for COVID-19. Conclusion: Cough HP, fever HP fever MESHD and being 50 to 69 years old are better predictors of symptomatic COVID-19 positivity during hospitalization. Despite published studies reporting a high prevalence SERO of lymphopenia HP lymphopenia MESHD among COVID-19 positive patients, lymphopenia HP lymphopenia MESHD is not associated with the risk of testing positive for COVID-19. Key Words: COVID-19, Predictors, Symptomatic, Hospitalized

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.